Pharmaceuticals
September 17, 2026
Frailty Doesn’t Factor in Semaglutide Outcomes September 17, 2026
A new secondary analysis of the SELECT trial pushes back on the instinct for avoiding new semaglutide prescriptions in frail patients after finding that the drug delivered its CV benefits regardless of frailty.
Artificial Intelligence
September 14, 2026
The Queen Arrives With AI-ECG for Urgent MI September 14, 2026
Many heart attack patients still miss the window for life-saving treatment because of diagnostic delays, but that’s changing with the FDA’s De Novo authorization of Powerful Medical’s Queen of Hearts AI-ECG model that detects STEMI and its harder-to-spot equivalents.
Cardiogenetics
September 10, 2026
Can Polygenic Risk Scores Uncover Hidden CVD? September 10, 2026
It’s rare that one gene causes CVD, just as it’s rare for one CV condition to occur in isolation. In a recent JACC issue, researchers show that […]
